Objective:To evaluate the effectiveness and safety of idarubicin for acute myeloid leukemia(AML).Method:By using the Cochrane system evaluation method,we collected the randomized controlled trials(RCTs)of idarubicin for de novo AML.After quality assessment and data extraction,the Meta-analysis was performed using RevMan 5.2software.Result:Nine studies were collected.Meta-analysis showed that although there was no significant difference between idarubicin versus daunorubicin in complete remission rate(P=0.12...